COMMUNIQUÉS West-GlobeNewswire

Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
07/05/2025
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces [...]
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
07/05/2025
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher Edinburgh, UK, 7 May 2025 - Trogenix Ltd (“Trogenix”), a pioneering [...]
Valitor Presents Multiple Preclinical Datasets on the Potential of its Innovative Anti-VEGF Therapy Dosed Twice Yearly for Wet AMD at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
07/05/2025
-VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs -VLTR-559 shown to be [...]
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology
07/05/2025
Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today [...]
Counslr Partners with Sack the Stigma to Expand Mental Health Wellness Resources
07/05/2025
Launch Coincides with Mental Health Awareness Month to Amplify Focus on Mental Well-being NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Counslr, a leading digital mental health company , and Sack the Stigma, a mental [...]
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
07/05/2025
PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in [...]
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
07/05/2025
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate [...]
Erasca to Present at the Bank of America Securities Health Care Conference
07/05/2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
07/05/2025
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
07/05/2025
SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
CorVista Health Announces European Respiratory Journal Publication Detailing Validation of its Non-Invasive Test for Pulmonary Hypertension
07/05/2025
Data demonstrates CorVista’s proprietary machine-learned algorithm detects elevated mean pulmonary artery pressure (mPAP) with strong sensitivity and specificity across diverse patient populations BETHESDA, Md., May 07 [...]
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
07/05/2025
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical [...]
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
07/05/2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
07/05/2025
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One [...]
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
07/05/2025
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, [...]
Castle Biosciences Celebrates Skin Cancer Awareness Month
07/05/2025
The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor [...]
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
07/05/2025
-- First quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI [...]
Lirum Therapeutics Announces New LX-101 Data in Thyroid Eye Disease Selected for Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
07/05/2025
New York, NY, May 07, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new [...]
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
07/05/2025
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 [...]

Pages